MYGN's GeneSight Test Proven Superior to TAU: Stock to Gain?

Key Takeaways Myriad Genetics' GeneSight test showed superiority over treatment-as-usual in major depression.A meta-analysis of six trials with 3,532 patients highlighted MYGN's GeneSight test's clinical benefits.Patients using MYGN's GeneSight were 41% more likely to achieve remission and 30% more likely to respond.Myriad Genetics, Inc. (MYGN) recently published results from a meta-analysis in the Journal of Clinical Psychopharmacology, stating the superiority of the company’s GeneSight Psychotropic test o ...